O’Brien GL, et al. Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland. Clin Breast Cancer. 2019;19(3):e440–51.

Article  CAS  PubMed  Google Scholar 

Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Waller CF, Mobius J, Fuentes-Alburo A. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. Br J Cancer. 2021;124(8):1346–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rojas L, et al. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. Plos One. 2020;15(2): e0227961.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee WC, et al. Economic analysis of intravenous vs. subcutaneously administered trastuzumab for the treatment of HER2+ early breast cancer in Malaysia. Adv Breast Cancer Res. 2016;05(01):1–13.

Article  Google Scholar 

Pan JW, et al. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nat Commun. 2020;11(1):6433.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trastuzumab as an adjuvant therapy for early breast cancer and economic evaluation 013/2016. Malaysia: Malaysian Health Technology Assessment Section (MaHTAS), Medical Development Division, Ministry of Health Malaysia; 2016. Available from http://www.moh.gov.my. Accessed 24 March 2022

Clinical Practice Guidelines (CPG). Management of Breast Cancer MOH/P/PAK/432.19(GU)-e. 3rd ed. Malaysia: Malaysian Health Technology Assessment Section (MaHTAS), Medical Development Division, Ministry of Health Malaysia; 2019. Available from http://www.acadmed.org.my. Accessed 24 March 2022.

Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olofsson S, et al. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast. 2016;29:140–6.

Article  PubMed  Google Scholar 

Tjalma WAA, et al. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit. Eur J Obstet Gynecol Reprod Biol. 2018;221:46–51.

Article  CAS  PubMed  Google Scholar 

Lammers P, et al. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets. Pharmaceuticals (Basel). 2014;7(9):943–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quek, David. The Malaysian Health Care System: A Review. 2014

Jamilah Yusoff AI. Out of pockets spending among breast cancer women receiving out-patient treatment in a tertiary teaching hospital in Kuala Lumpur Malaysia. Malaysian J Public Health Med. 2021;21(3):240–9.

Article  Google Scholar 

Ismael G, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13(9):869–78.

Article  CAS  PubMed  Google Scholar 

Mylonas C, et al. Cost-minimization analysis of trastuzumab intravenous versus trastuzumab subcutaneous for the treatment of patients with HER2+ early breast cancer and metastatic breast cancer in Greece. Value Health. 2014;17(7):A640–1.

Article  CAS  PubMed  Google Scholar 

Roche, Package Insert For Malaysia: HERCEPTIN (SC), 2015.

Roche, Package Insert For Malaysia: HERCEPTIN (IV), 2022.

Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469.

PubMed  PubMed Central  Google Scholar 

Huebel K, Kron F, Lux MP. Biosimilars in oncology: effects on economy and therapeutic innovations. Eur J Cancer. 2020;139:10–9.

Article  CAS  Google Scholar 

Chong SC, Rajah R, Chow PL, Tan HC, Chong CM, Khor KY, Lee WP, Tan WY. Perspectives toward biosimilars among oncologists: A Malaysian survey. J Oncol Pharm Pract. 2022;13:10781552221104773. https://doi.org/10.1177/10781552221104773

Mercier G, Naro G. Costing hospital surgery services: the method matters. Plos One. 2014;9(5): e97290.

Article  PubMed  PubMed Central  Google Scholar 

Clinical Practice Guidelines (CPG). Ministry of Health Systemic Therapy Protocol MOH/P/IKN/02.17 (BK) Third Edition. Malaysia: 2016, Malaysia. Available from http://www.moh.gov.my. Accessed 20 June 2023

Jackisch C, et al. Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers. Geburtshilfe Frauenheilkd. 2015;75(6):566–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blackwell K, Gligorov J, Jacobs I, Twelves C. The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer. Clin Breast Cancer. 2018;18(2):95–113. https://doi.org/10.1016/j.clbc.2018.01.006

North RT, et al. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. Clinicoecon Outcomes Res. 2015;7:423–30.

PubMed  PubMed Central  Google Scholar 

De Cock E, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389–97.

Article  PubMed  PubMed Central  Google Scholar 

Azzani M, et al. Provider costs of treating colorectal cancer in government hospital of Malaysia. Malays J Med Sci. 2019;26(1):73–86.

PubMed  PubMed Central  Google Scholar 

Raman S, et al. Household catastrophic health expenditure from oral potentially malignant disorders and oral cancer in public healthcare of Malaysia. Asian Pac J Cancer Prev. 2022;23(5):1611–8.

Article  PubMed  PubMed Central  Google Scholar 

Lin H, LC, Yeh T et al. Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time-motion study with mixed-method research. BMJ Open. 2023;13:e059288.

Article  PubMed  PubMed Central  Google Scholar 

Pivot X, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962–70.

Article  CAS  PubMed  Google Scholar 

Ahmad R, Hasan J. Public health expenditure, governance and health outcomes in Malaysia. Jurnal Ekonomi Malaysia. 2016;50:29–40. https://doi.org/10.17576/JEM-2016-5001-03

Hedayati E, et al. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden. Plos One. 2019;14(2): e0211783.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cesarec A, Likic R. Budget impact analysis of biosimilar trastuzumab for the treatment of breast cancer in Croatia. Appl Health Econ Health Policy. 2017;15(2):277–86.

Article  PubMed  Google Scholar 

Lee SM, et al. Budget impact of switching to biosimilar trastuzumab (CT-P6) for the treatment of breast cancer and gastric cancer in 28 European countries. BioDrugs. 2019;33(4):423–36.

Article  PubMed  Google Scholar 

Ponzetti C, et al. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227–33.

PubMed  PubMed Central  Google Scholar 

Lopez-Vivanco G, et al. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clin Transl Oncol. 2017;19(12):1454–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dent S, et al. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Curr Oncol. 2019;26(1):e70–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raman S, Shafie AA, Abraham MT, Kiong SC, Maling TH, Rajendran S, Cheong SC. Time-to-treatment of oral cancer and potentially malignant oral disorders: Findings in Malaysian public healthcare. Dent J (Basel). 2022;10(11):199. https://doi.org/10.3390/dj10110199